Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 28, 2024
Emerging Company Profile

Red Queen: A new approach to viral fusion proteins

Apple Tree Partners launches infectious disease company with stapled lipopeptide tech for blocking viral fusion
BioCentury | May 7, 2024
Emerging Company Profile

Xaira’s $1B AI play: de novo antibodies now, causal biology to follow

Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery
BioCentury | Aug 19, 2023
Discovery & Translation

PROTAC using an alt. E3 ligase; plus lung-targeted mRNA COVID vaccine and more

BioCentury’s roundup of translational innovations
BioCentury | Jul 15, 2023
Discovery & Translation

Armgo molecule prevents cardiogenic dementia; Ten63’s improved HIV-1 Abs and more

BioCentury’s roundup of translational innovations
BioCentury | Jul 7, 2023
Discovery & Translation

Smaller gene editors, Resilience’s cell-free antibody discovery platform and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 10, 2023
Discovery & Translation

Bacteriophage therapy for liver dysfunction; plus Genentech’s pan-TEAD inhibitor and more

BioCentury’s roundup of translational news
BioCentury | May 26, 2023
Discovery & Translation

Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID vaccine and more

BioCentury’s roundup of translational news
BioCentury | May 3, 2023
Distillery Therapeutics

Multispecific shark nanobodies for COVID-19

BioCentury | May 3, 2023
Distillery Therapeutics

Bispecific neutralizing antibody targeting COVID-19 "coldspots"

Items per page:
1 - 10 of 199